Page last updated: 2024-08-24

1,5-anhydroglucitol and gsk2141795

1,5-anhydroglucitol has been researched along with gsk2141795 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agarwal, R; Babar, S; Blagden, S; Carme, S; Chen, M; Curry, E; Dina, R; El-Bahrawy, MA; Gabra, H; Gungor, H; Krachey, E; Madison, S; Morris, SR; Pickford, E; Rama, N; Saleem, A; Salinas, C; Santiago-Walker, A; Smith, DA; Stronach, EA	1

Trials

1 trial(s) available for 1,5-anhydroglucitol and gsk2141795

Article	Year
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:12 Topics: Antineoplastic Agents; Biomarkers; Biopsy; Blood Glucose; Deoxyglucose; Diamines; Drug Interactions; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Humans; Oncogene Protein v-akt; Positron-Emission Tomography; Pyrazoles; Radiopharmaceuticals; Treatment Outcome	2015

Article

Year

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:12

Topics: Antineoplastic Agents; Biomarkers; Biopsy; Blood Glucose; Deoxyglucose; Diamines; Drug Interactions; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Humans; Oncogene Protein v-akt; Positron-Emission Tomography; Pyrazoles; Radiopharmaceuticals; Treatment Outcome

2015